Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Portola

This page shows the latest Portola news and features for those working in and with pharma, biotech and healthcare.

CHMP backs Lynparza in breast cancer, Dupixent in asthma

CHMP backs Lynparza in breast cancer, Dupixent in asthma

There was a raft of other significant recommendations from the CHMP at its latest meeting, including one for Portola’s Ondexxya (andexanet alfa), which if fully approved by the EMA will

Latest news

  • CHMP backs first-line use for AZ’s Tagrisso in lung cancer CHMP backs first-line use for AZ’s Tagrisso in lung cancer

    The three drugs in question are Portola’s anticagulant Dexxience (betrixaban), Radius’ osteoporosis candidate Eladynos (abaloparatide) and AB Science’s Alsitek (masitinib), filed for neurodegenerative disease amyotrophic lateral sclerosis (ALS)

  • ViiV’s two-drug HIV combo backed by CHMP ViiV’s two-drug HIV combo backed by CHMP

    There was bad news for three other companies, with the CHMP issuing negative opinions for Portola’s Dexxience (betrixaban) for the prevention of venous thromboembolism, Radius International’s osteoporosis candidate Eladynos

  • Bad news for Portola as CHMP considers Factor Xa drugs Bad news for Portola as CHMP considers Factor Xa drugs

    Portola Pharmaceuticals’ efforts to secure approval for its novel oral anticoagulant (NOAC) and reversal agent in Europe have hit another snag. ... Now, it seems that while applications for andexanet alfa may be getting back on track, it will likely be

  • Portola rejection hands advantage to Boehringer's Pradaxa Portola rejection hands advantage to Boehringer's Pradaxa

    The agency said that it also needs more time to complete its review of certain clinical amendments to Portola's post-marketing commitments that were submitted recently. ... Shares in Portola plunged on news of the FDA rejection, and the company is

  • Boehringer’s Praxbind granted accelerated approved by FDA Boehringer’s Praxbind granted accelerated approved by FDA

    However, competition is also coming from rivals such as Portola Pharmaceuticals, which is currently undertaking phase III trials of andexanet alfa, which has shown to reverse the effect of other

More from news
Approximately 4 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Licence, collaboration. 237.5. Portola Pharmaceuticals/  HealthCare Royalty Partners. AndexXa (andexanet alfa) - Factor Xa inhibitor antidote (phase IIIb/IV).

  • Deal Watch February 2016 Deal Watch February 2016

    merger. 106. † Portola Pharmaceuticals/ BMS| Pfizer. andexanet alfa as an antidote for apixaban and other Factor Xa inhibitors (pre-reg).

  • Modern anticoagulants threaten status quo Modern anticoagulants threaten status quo

    Betrixaban. Betrixaban (Portola Pharmaceuticals) is a long-acting oral factor Xa inhibitor that entered phase III trial development for VTE prevention in medically ill patients in March 2012. ... Portola is also developing PRT 064445, which is an

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • Sanifit appoints Alexander Gold chief medical officer Sanifit appoints Alexander Gold chief medical officer

    He joins the Palma-headquartered company from Portola Pharmaceuticals, where he served as a senior vice president and head of clinical development. ... Prior to his time at Portola, Dr Gold was head of clinical development at Reata Pharmaceuticals and

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
The Good Ideas Group

Remarkable but responsible creative work. We're most passionate about the pursuit of original, powerful ideas that our clients can harness...

Latest intelligence

Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
Six ways to improve diversity in clinical trials
Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...

Quick links